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Abstract
Background Chronic heart failure (CHF) is associated with skeletal muscle abnormalities contributing to exercise intolerance,
muscle loss, and negative impact on patient prognosis. A primary role has been proposed for mitochondrial dysfunction, which
may be induced by systemic and tissue inﬂammation and further contribute to low insulin signalling. The acylated form of the
gastric hormone ghrelin (AG) may improve mitochondrial oxidative capacity and insulin signalling in both healthy and diseased
rodent models.
Methods We investigated the impact of AG continuous subcutaneous administration (AG) by osmoticminipump (50 nmol/kg/day
for 28 days) compared with placebo (P) on skeletal muscle mitochondrial enzyme activities, mitochondrial biogenesis regulators
transcriptional expression and insulin signalling in a rodent post-myocardial infarction CHF model.
Results No statistically signiﬁcant differences (NS) were observed among the three group in cumulative food intake.
Compared with sham-operated, P had low mitochondrial enzyme activities, mitochondrial biogenesis regulators transcripts,
and insulin signalling activation at AKT level (P < 0.05), associated with activating nuclear translocation of pro-inﬂammatory
transcription factor nuclear factor-κB. AG completely normalized all alterations (P< 0.05 vs P, P = NS vs sham-operated). Direct
AG activities were strongly supported by in vitro C2C12 myotubes experiments showing AG-dependent stimulation of
mitochondrial enzyme activities. No changes in mitochondrial parameters and insulin signalling were observed in the liver in
any group.
Conclusions Sustained peripheral AG treatment with preserved food intake normalizes a CHF-induced tissue-speciﬁc cluster
of skeletal muscle mitochondrial dysfunction, pro-inﬂammatory changes, and reduced insulin signalling. AG is therefore a
potential treatment for CHF-associated muscle catabolic alterations, with potential positive impact on patient outcome.
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Introduction
Incidence and prevalence of chronic heart failure (CHF) are
increasing worldwide, and CHF-associated morbidity and
mortality are a major health problem.1,2 CHF commonly
causes skeletal muscle (SM) metabolic and functional alter-
ations that lead to exercise intolerance and ultimately muscle
loss with strong negative impact on patient outcome.3–10
Altered energy metabolism with low mitochondrial oxidative
capacity has been proposed to play a primary role in CHF-
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induced SM changes.3,11,12 Cardiac and systemic pro-
inﬂammatory signalling activation has been conversely
hypothesized to contribute to low tissue mitochondrial
function,13,14 and skeletal muscle inﬂammation and mito-
chondrial dysfunction could further impair insulin signal-
ling15–18 thereby collectively enhancing muscle catabolism.
Effective therapeutic strategies to counteract CHF-induced
SM mitochondrial dysfunction and its potential metabolic
consequences are therefore urgently needed.
The gastric hormone acylated ghrelin (AG) has orexigenic
effects and complex metabolic activities that may include
stimulation of SM mitochondrial oxidative capacity and
insulin signalling in both healthy and diseased rodent
models.19–22 Despite potential negative effects on circulating
glucose reported in human and experimental models due to
potential glucogenic activities,19,20,23 AG has been therefore
extensively studied and increasingly suggested as potential
anti-catabolic treatment under chronic disease conditions
associated with loss of body and muscle mass.8,22,24–26 We
and others have shown beneﬁcial effects of AG on body
weight, muscle mass, and systemic inﬂammation in cancer
and renal cachexia models.21,27,28 In experimental chronic
kidney disease, we speciﬁcally demonstrated that sustained
peripheral AG administration enhances skeletal muscle
mitochondrial function also independently of food intake.21
No information is, however, available on potential effects of
AG administration on skeletal muscle mitochondrial function
and insulin signalling in CHF. In addition, no studies investi-
gated potential AG effects on skeletal muscle inﬂammation
as potential mediator of AG metabolic activities in cachexia-
inducing diseases in vivo.
In the current study, we therefore investigated the impact
of continuous 28 day AG subcutaneous administration on SM
mitochondrial enzyme activities, transcriptional expression
of mitochondrial biogenesis regulators as well as insulin
signalling and pro-inﬂammatory pathways in a rodent post-
myocardial infarction (IMA) CHF model. Direct AG effects on
mitochondrial function and enzyme activities were further
veriﬁed in vitro in C2C12 myotubes, whereas animals were
studied in vivo at AG doses reported to prevent global
alterations in food intake through the whole experimental
period.29 Because AG was previously reported to reduce
systemic inﬂammation markers in different chronic disease
models27 and systemic inﬂammation may be activated in
CHF with potential negative impact on SM inﬂammatory
pathways and mitochondrial and metabolic dysfunction,13,14
we further examined whether activating nuclear transloca-
tion of the master pro-inﬂammatory transcription factor
nuclear factor-κB (NFκB) is altered in CHF and normalized
by AG. The same parameters were ﬁnally investigated in the
liver to determine potential tissue distribution and speciﬁcity
of AG activities because differential acylated ghrelin effects
were reported at hepatic level with potential to negatively
affect plasma metabolic proﬁle.19,20,23
Materials and methods
Experimental protocol and measurements
Animal surgery and treatments
All procedures were approved by the competent ethics
committee (Ladesamt fur Gesundheit und Soziales Berlin,
Germany; permit number G 0116/05). The study was de-
signed to determine the effects of ghrelin or ghrelin ana-
logues on body weight and composition in chronic heart
failure, and part of the study results have been published
elsewhere.29,30 215–230 g male Sprague Dawley rats (Harlan-
Winkelman, Borchen, Germany) underwent surgical proce-
dures with thoracotomy and either coronary artery ligation
(IMA) or sham operation with thoracotomy and cardiac expo-
sure without ligation of the coronary artery (Control).29,30 All
rats were treated with buprenorphine for 2 days following
surgery for analgesia; 24 h mortality was 31%. Surviving
animals were caged individually and fed standard chow under
a 12 h light cycle; all rats were treatedwith furosemide starting
14 days after surgery.29,30 After two additional weeks, IMA
animals were further randomized (n = 18 each) to receive
either placebo (IMA-P) or human ghrelin at 50 nmol/kg/day
(IPSEN Pharmaceuticals; IMA-AG) via osmotic minipumps
implanted subcutaneously on the back (Charles River, Sulzfeld,
Germany); control animals received placebo via the same
route (n = 14). After 14 day infusions, minipumps were
replaced on Day 42 from surgery; animals were then sacriﬁced
at Day 56 from surgery after identical additional 14 day
infusions. Animal body weight and food intake were recorded
twice weekly throughout the study period; body weight
changes were analysed and compared among groups during
the ﬁrst week of each infusion period, that is, at Days 28–36
and 42–50 after initial surgery. Echocardiography was
performed prior to sacriﬁce, using am 15 MHz probe and
an Acuson Sequoia system (Siemens, Erlangen, Germany);
animals with infarct size less than 25% of left ventricle were
excluded from analyses (n = 5).
Cytochrome c oxidase and citrate synthase activities and RNA
analysis
Mitochondrial cytochrome c oxidase and citrate synthase
enzyme activities were measured spectrophotometrically
from muscle homogenates as referenced.31 Total RNA was
isolated from 40–50mg of gastrocnemius muscle (Tri Reagent,
MRC, Cincinnati, OH, USA). Transcript levels of regulators
of mitochondrial biogenesis and lipid metabolism were mea-
sured by real-time polymerase chain reaction (7900 Sequence
Detection System, Applied Biosystems, Applied Biosystems
Italia, Monza, Italy) as referenced.21 Brieﬂy, 1 mg of total
RNA was reverse-transcribed (RNA Reverse Transcription
KIT, Applied Biosystems) and ampliﬁed using primers
(300 nM) and probes (50 nM) selected using the Primer
Express Software (Applied Biosystems). Primers for PGC-1α
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ampliﬁcation were as follows: forward: AGCAAGCTCTGATGCT
CTGAAGGA; reverse: ACCGAAGTGAGGTGCTTATGCAGT. The
probe sequence for PGC-1α detection was TTCCAGAAGTC
AGCGGCCTTGTGTCAA. Primers for PPARγ ampliﬁcation were
as follows: forward: ACCAGGGAGTTCCTCAAAAGC; reverse:
GCAAACTCAAACTTAGGCTCCATAA. The probe sequence for
PPARγ detection was TGCGGAAGCCCTTTGGTGA. The refer-
ence gene used was 28S rRNA.19,21 Target and housekeeping
genes were ampliﬁed separately, and their ﬁnal quantitation
was achieved using a relative standard curve. Results for each
gene were divided by the corresponding 28S rRNA abundance
and expressed as arbitrary units.
Nuclear factor-κB nuclear content, AKT insulin signalling, and
plasma biochemical proﬁle
Nuclear protein extracts for measurement of nuclear NFκB
were obtained as previously reported.32 Protein concentra-
tion in all samples was measured by spectrophotometer
(BCA Protein Assay Reagent, Pierce, Rockford, IL, USA). For
measurement of tissue p65 NFκB subunit a commercially
available kit was used following manufacturer instructions
(TransAM, Active Motif North America, Carlsbad, CA, USA).
Total (T) and phosphorylated (P: activated) AKT muscle
protein contents were determined using western blotting as
previously described.20 The P/T ratio was calculated as a
marker of tissue AKT activation, and results were expressed
as a percentage of sham value. Plasma insulin concentration
was measured by enzyme-linked immunosorbent assay
(Ultrasensitive ELISA; DRG, Springﬁeld, NJ). Plasma glucose
and triglycerides levels were determined by standard enzy-
matic colorimetric assays.21
C2C12 myotube experiments
C2C12 myoblasts were differentiated in myotubes as pre-
viously reported.33,34 After 4 day incubation periods with
differentiation medium and 18 h starvation, they were treated
with AG (0.1 or 1 μmol/L) for 48 h, followed by collection
and processing. Adenosine triphosphate (ATP) production
from cell preparations was measured by luciferin-luciferase
luminometric assay,33–35 and cytochrome c oxidase and cit-
rate synthase activities were measured spectrophotometri-
cally as referenced.19
Statistical analysis
All values are expressed as mean ± SEM. Comparison of pa-
rameters among the three groups were performed using
one-way analysis of variance followed by the Tukey post-
hoc test. P values <0.05 were considered statistically signiﬁ-
cant. Weight changes within each group were compared
using paired t-test.
Results
Body weight, food intake, and plasma metabolic proﬁle
No statistically signiﬁcant differences in body weight among
groups were observed at any time, and body weight was
comparable at time of surgery in all groups despite a less
pronounced body weight gain in the last ghrelin infusion
period (Table 1). A general overall decline in food intake
was observed for all groups between the ﬁrst and the second
ghrelin infusion period, but cumulative food intake remained
comparable among the three groups during the whole
infusion periods (Table 2). Plasma insulin, glucose, and
triglycerides concentrations were comparable in all study
groups (Table 3).
Skeletal muscle mitochondrial enzyme activities and mito-
chondrial biogenesis transcript levels (Figure 1)
Myocardial infarction with placebo had lower skeletal muscle
activities of both cytochrome c oxidase and citrate synthase
(P < 0.05 vs control; Figure 1). This alteration was associated
with lower transcript levels of master regulators of mitochon-
drial biogenesis and lipid oxidation PGC-1a and PPAR-gamma
(Figure 2). Ghrelin treatment was in turn associated with
higher activities of both enzymes compared with IMA-P
Table 1 Body weights
Time Sham IMA-P IMA-AG
n = 14 n = 18 n = 18
Body weight at
surgery (g)
T0 227.9 ± 2.5 225.0 ± 2.1 227.4 ± 1.6
Body weight at
start of treatment
(g)
T28 322.5 ± 7.4 311.4 ± 5.8 316.1 ± 3.7
Final body weight
(g)
T56 357.8 ± 7.8 339.4 ± 7.5 352.2 ± 5.4
Effects of continuous subcutaneous administration of gastric
hormone acylated ghrelin (50 nmol/kg/day for 28 days) by osmotic
minipump in a rodent post-myocardial infarction chronic heart
failure model on body weight. No statistical signiﬁcant differences
were observed among groups. Mean ± SEM, n = 14–18/group.
IMA-AG, myocardial infarction with gastric hormone acylated
ghrelin; IMA-P, myocardial infarction with placebo
Table 2 Food intake
Time Sham IMA-P IMA-AG
n = 14 n = 18 n = 18
Average
food intake
(g/100 g/day)
T28-T56 5.43 ± 0.07 5.32 ± 0.065 5.48 ± 0.5
Effects of continuous subcutaneous administration of gastric
hormone acylated ghrelin (50 nmol/kg/day for 28 days) by osmotic
minipump in a rodent post-myocardial infarction chronic heart
failure model on average daily food intake during treatment. No
statistical signiﬁcant differences were observed among groups.
Mean ± SEM, n = 14–18/group. IMA-AG, myocardial infarction
with gastric hormone acylated ghrelin; IMA-P, myocardial infarc-
tion with placebo
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(P < 0.05 vs IMA-P, P = NS vs control; Figure 1). Transcript
levels of PGC-1a were also higher after AG treatment than
in IMA-P animals (P < 0.05 vs IMA-P, P = NS vs control)
whereas no effects of AG were observed on PPARγ expres-
sion (Figure 2).
Skeletal muscle nuclear factor-κB nuclear content and AKT
phosphorylation (Figure 2)
Higher skeletal muscle nuclear NFκB content and lower AKT
phosphorylation were observed in IMA-P rats compared with
control animals. Ghrelin treatment was in turn associated
with normalized nuclear NFκB and AKT phosphorylation (both
P < 0.05 for IMA-AG vs IMA-P; P = NS for IMA-AG vs control).
Gastric hormone acylated ghrelin activities in vitro in C2C12
myotubes (Figure 3)
In order to determine potential direct effects of AG in skeletal
muscle tissue, we further investigated its mitochondrial
activities in vitro in C2C12 myotubes. Consistent with direct
mitochondrial effects in skeletal muscle tissue, AG incubation
resulted in enhanced mitochondrial ATP production as well
as cytochrome c oxidase and citrate synthase activities
(P < 0.05).
Liver mitochondrial enzyme activities and mitochondrial
biogenesis transcript levels (Figure 4)
At variance with gastrocnemius muscle, liver activities of both
cytochrome c oxidase and citrate synthase were not affected
Table 3 Animal characteristics
Time Sham IMA-P IMA-AG
n = 14 n = 18 n = 18
Plasma glucose
(mg/dL)
T56 112 ± 5 107 ± 9 121 ± 6
Plasma insulin
(μU/mL)
T56 12.3 ± 2.1 12.8 ± 0.9 11.7 ± 1.3
Plasma triglycerides
(mg/dL)
T56 0.73 ± 0.08 0.61 ± 0.04 0.72 ± 0.06
Effects of continuous subcutaneous administration of gastric
hormone acylated ghrelin (50 nmol/kg/day for 28 days) by osmotic
minipump in a rodent post-myocardial infarction chronic heart
failure model on ﬁnal glucose, insulin, and triglyceride plasma
levels. No statistical signiﬁcant differences were observed among
groups. Mean ± SEM, n = 14–18/group. IMA-AG, myocardial
infarctionwith gastric hormone acylated ghrelin; IMA-P, myocardial
infarction with placebo
Figure 1 Skeletal muscle mitochondrial enzyme activities and mitochondrial biogenesis transcript levels. Effects of continuous subcutaneous admin-
istration of gastric hormone acylated ghrelin (50 nmol/kg/day for 28 days) by osmotic minipump in a rodent post-myocardial infarction chronic heart
failure model on citrate synthase (A) and cytochrome c oxidase (B) activity and on PGC1α (C) and PPARγ (D) gene expression in skeletal muscle. a.u.,
arbitrary units, *P < 0.05 versus other groups, mean ± SEM, n = 14–18/group. IMA-P, myocardial infarction with placebo; IMA-AG, myocardial infarc-
tion with gastric hormone acylated ghrelin.
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by IMA or AG treatment and were comparable in the three
study groups. Transcript levels of master regulators of
mitochondrial biogenesis and lipid oxidation were similarly
comparable in control, IMA-P, and IMA-AG animals. Further
supporting tissue-speciﬁc CHF and AG activities, no changes
were observed in any groups also for NFκB nuclear transloca-
tion and AKT phosphorylation.
Discussion
The current study demonstrated that (a) sustained peripheral
acylated ghrelin treatment in a rodent model of IMA-induced
chronic heart failure completely normalized a cluster of
skeletal muscle mitochondrial dysfunction and tissue pro-
inﬂammatory and insulin-desensitizing changes; (b) acylated
ghrelin appears to act at least in part directly at skeletal
muscle level because its mitochondrial effects are fully
reproduced in vitro in muscle cells; (c) effects of chronic heart
failure per se as well as those of acylated ghrelin treatment
on energy metabolism, inﬂammation, and insulin signalling
are tissue-speciﬁc and do not occur at hepatic level.
Mitochondrial dysfunction, inﬂammation, and insulin
resistance have emerged in recent years as potentially
causally related abnormalities with strong negative impact
on skeletal muscle metabolism and function in chronic heart
failure.3,10–15,17 Comprehensive normalization of CHF-induced
alterations therefore indicates acylated ghrelin as a novel
potential treatment for skeletal muscle dysfunction and its
negative prognostic impact in CHF patients.4,6,7 The current
ﬁndings are notably in excellent agreement with previous
reports of mitochondrial effects of acylated ghrelin with en-
hanced skeletal muscle oxidative enzyme activities in healthy
rodents19 and normalized enzyme activities in experimental
chronic kidney disease.21 Anti-inﬂammatory and insulin-
sensitizing AG activities were conversely also reported in
healthy and obese rodent models20,27,36 and in vitro in re-
sponse to pharmacological induction of muscle cell damage.25
Causal links and vicious cycles likely contribute to associations
between muscle mitochondrial dysfunction, inﬂammation,
and low insulin signalling in CHF. In particular, systemic pro-
inﬂammatory changes are reported to occur in CHF, and they
could lead to both mitochondrial and insulin signalling abnor-
malities in skeletal muscle.13,14 Mitochondrial dysfunction is,
however, in turn also a potential primary cause of tissue
Figure 2 Skeletal muscle nuclear factor-κB (NFκB) nuclear content and AKT phosphorylation. Effects of continuous subcutaneous administration of AG
(50 nmol/kg/day for 28 days) by osmotic minipump in a rodent post-myocardial infarction chronic heart failure model on nuclear NF-κB (A), tissue
triglycerides (B), and pAKT (C) levels in skeletal muscle. *P < 0.05 vs. other groups, mean ± SEM, n = 14–18/group. IMA-P, myocardial infarction with
placebo; IMA-AG, myocardial infarction with gastric hormone acylated ghrelin.
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inﬂammation and insulin resistance through enhanced reac-
tive oxygen species generation by damaged organelles.17,18,34
A primary role of improved mitochondrial function in global
tissue AG activities in the current model is strongly supported
by AG-induced in vitro enhancement of mitochondrial ATP
production and oxidative capacity of both Krebs cycle and
respiratory chain enzymes. In the current study, we notably
also observed a CHF-induced transcriptional suppression of
master mitochondrial biogenesis and oxidative metabolism
regulators; PGC1-α but not PPARγ expression was selectively
normalized by AG treatment, and this ﬁnding is in agreement
with a direct involvement of mitochondrial biogenesis in the
observed stimulation of mitochondrial parameters. Further
studies should directly conﬁrm this hypothesis.
In the current study, we investigated acylated ghrelin
effects in the established IMA-induced CHF model, and all
studied animals showed evidence of impaired left-ventricular
function. Under the current conditions, all groups had com-
parable body weight and food intake at different experimen-
tal stages. Consistent with CHF-induced catabolism, P-treated
animals, however, had less pronounced growth and total
weight gain during the second part of the acylated ghrelin
infusion treatment (Day 42–56 from surgery; not shown)
despite comparable food intake. Less pronounced growth
was conversely not observed in AG-treated animals, consistent
with potential muscle mass preservation through the ob-
served muscle anti-catabolic effects. Skeletal muscle weight
was not available in the current study, and further experi-
ments should directly aim at dissecting potential differential
contributions of lean and fat tissues in acylated ghrelin
anabolic activities.
Assessment of potential tissue-speciﬁcity of CHF-induced
metabolic alterations as well as differential acylated ghrelin
effects in different tissues was an additional aim of the
current study. At variance with skeletal muscle, CHF had no
relevant impact on hepatic mitochondrial, inﬂammatory, and
insulin signalling parameters. This ﬁnding is consistent with
available reports of clinically relevant hepatic abnormalities
following acute heart failure and hemodynamic changes37
while chronic alterations in heart function may only result in
liver metabolic alterations at late disease stages. Lack of AG
activities in liver tissue is also consistent with tissue-speciﬁc
metabolic effects of AG on skeletal muscle and liver,19,20 with
potentially negative effects on hepatic insulin signalling and
stimulation of hepatic glucogenic pathways in healthy lean
rodents.19,20 Under the current experimental conditions, lack
of changes in hepatic metabolic parameters was also associ-
ated with no negative impact of AG on plasma glucose,
Figure 3 Gastric hormone acylated ghrelin (AG) activities in vitro in C2C12 myotubes. Effects of the incubation with increasing concentrations of AG or
unacylated ghrelin versus control (Ct) on citrate synthase (A) and cytochrome c oxidase (B) activity and adenosine triphosphate (ATP) synthesis rate (C)
in C2C12myotubes. PPKM, pyruvate + palmitoyl-L-carnintine + α-ketoglutarate + malate; PCM, palmitoyl-L-carnintine + malate; GM, glutamate + malate;
SR, succinate + rotenone. *P < 0.05 versus Ctrl,
$
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insulin, and triglycerides. These ﬁndings are in agreement
with lack of effects in chronic kidney disease models,21
thereby collectively supporting the concept that AG adminis-
tration under various chronic disease conditions is metaboli-
cally safe and does not alter plasma biochemical proﬁle as
well as pivotal liver metabolic pathways.
In conclusion, we demonstrated that sustained peripheral AG
treatment normalizes a CHF-induced cluster of skeletal muscle
mitochondrial dysfunction, pro-inﬂammatory changes, and re-
duced insulin signalling. Acylated ghrelin activities at skeletal
muscle level appear to be at least partly direct and independent
because mitochondrial effects are fully reproduced in vitro in
muscle cells. The metabolic impact of chronic heart failure per
se and acylated ghrelin treatment are tissue-speciﬁc and do
not occur at hepatic level. These ﬁndings collectively indicate
AG as a potential novel treatment for CHF-associated muscle
catabolic abnormalities, with potential positive impact on skel-
etal muscle function and patient outcome.
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